Semaglutide

FDA Approved

Semaglutide

Aliases
Ozempic, Wegovy, Rybelsus
Administration
Subcutaneous injection (weekly), Oral tablet (daily)

Research and regulatory

Development stage

FDA approved: T2D (2017), obesity (2021), CV risk reduction (2024).

Legal and regulatory

FDA approved across multiple indications.

Side effects

GI symptoms predominant; rare pancreatitis